A Phase 2/3 interventional study of Flebogamma® 5% DIF and Placebo in Post-polio Syndrome, sponsored by Instituto Grifols, S.A.. Terminated at 21 sites in 9 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-05.
Sponsored by Instituto Grifols, S.A. (part of Grifols) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This was a multicenter, prospective, randomized, placebo-controlled, double-blind, parallel group clinical trial with adaptive dose selection in participants with post-polio syndrome (PPS).
The main purpose of this study was to select a dose of Flebogamma® 5% DIF and confirm the efficacy of the selected Flebogamma® 5% DIF dose by assessing physical performance, as measured by Two-Minute Walk Distance (2MWD) test.
The study consisted of 2 stages, with each stage consisting of a screening period (up to 4 weeks), a treatment period (52 weeks), and a follow-up period (24 weeks).
28 studies on the registry are indexed under Postpoliomyelitis Syndrome; 3 are open to participants now.
This study's enrollment of 191 is above the median of 40 across 19 interventional studies indexed under Postpoliomyelitis Syndrome.
Browse Postpoliomyelitis Syndrome studies →Instituto Grifols, S.A. is the lead sponsor of 24 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received Flebogamma® 5% DIF 2 g/kg of body weight administered via intravenous (IV) infusion over 2 consecutive days (Flebogamma® 5% DIF 1 g/kg infused on Day 1, followed by Flebogamma® 5% DIF 1 g/kg infused on Day 2) every 4 weeks for 52 weeks.
Biological: Flebogamma® 5% DIF
Participants received Flebogamma® 5% DIF 1 g/kg of body weight administered via IV infusion on Day 1, followed by 20 mL/kg of matching placebo administered on a separate day, for a total dosing period of 2 consecutive days, every 4 weeks for 52 weeks. The order of 1 g/kg Flebogamma® 5% DIF or matching placebo was randomly determined for each participant and was the same for the participant for all infusion visits during the treatment period.
Biological: Flebogamma® 5% DIF · Drug: Placebo
Participants received matching placebo at a total dose of 40 mL/kg of body weight administered via IV infusion over 2 consecutive days. On Day 1, a dose of 20 mL/kg of matching placebo was given, followed by the second dose of 20 mL/kg of matching placebo on Day 2, administered every 4 weeks for 52 weeks.
Drug: Placebo
Participants received Flebogamma® 5% DIF 1 g/kg of body weight administered via IV infusion on Day 1, followed by 20 mL/kg of matching placebo administered on a separate day, for a total dosing period of 2 consecutive days, every 4 weeks for 52 weeks. The order of 1 g/kg of Flebogamma® 5% DIF or matching placebo was randomly determined for each participant and was the same for the participant for all infusion visits during the treatment period.
Biological: Flebogamma® 5% DIF · Drug: Placebo
Participants received matching placebo at a total dose of 40 mL/kg of body weight administered via IV infusion over 2 consecutive days. On Day 1, a dose of 20 mL/kg of matching placebo was given, followed by the second dose of 20 mL/kg of matching placebo on Day 2, administered every 4 weeks for 52 weeks.
Drug: Placebo
Human plasma-derived immunoglobulin
Also known as: immune globulin intravenous (human)
Matching placebo
Change From Baseline in Physical Performance Assessed by Two-Minute Walk Distance (2MWD) Test
The 2MWD was used to assess physical performance by measuring the distance that a participant can quickly walk at a self-preferred speed on an indoor flat, hard surface 30 m (100-ft) hallway in a period of 2 minutes. A positive change from baseline indicates improvement (i.e. a patient can walk farther). Increase in distance walked (in meters) indicates improvement.
Time frame: Baseline to Week 52
Change From Baseline in Pain Using Visual Analogue Scale (VAS) of Pain
VAS is a participant self-reported pain scale used to evaluate the pain level in a 24 hours period. The scale consists of a 100 millimeters (mm) scale where 100 mm stands for the worst imaginable pain and zero stands for no pain. Higher scores indicate severe pain. A negative change from baseline indicates improvement. LS mean and 95% (CI) were based on MMRM method.
Time frame: Baseline to Week 52
Change From Baseline in Health-Related Quality of Life (HRQoL) Assessed by Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) Physical Component Summary (PCS)
HRQoL SF-36 is participant self-reported survey.It yields 8-scale profile of functional health and well-being as well as physical and mental health summary measures. It consists of the subscales:physical functioning,limitations due to physical health,body pain,general health,vitality,social functioning,emotional problems, and mental health. Each domain score ranges from 0(worst) to 100(best),higher scores reflect better functional status.PCS is a subscale score \& give broader metric of physical HRQoL.PCS score ranges from 0 to 100 and is computed such that mean score of 50 corresponds to the general US population.Based on norm-based scoring,scores above 50 is better-than-average health \& below 50 is below-average health.Higher scores represents better physical health.Positive change from baseline indicates improvement.LS mean and 95% CI were based on MMRM.
Time frame: Baseline to Week 52
Change From Baseline in Endurance Assessed by Six-Minute Walk Distance (6MWD) Test
The 6MWD was used to assess physical performance by measuring the distance that a patient can quickly walk at maximal speed on a flat, hard surface 30 m (100-ft) hallway in a period of 6 minutes. A positive change from baseline indicates improvement (i.e., a patient can walk farther). Increase from baseline in distance walked (in meters) indicated improvement. LS mean and 95% CI were based on MMRM method.
Time frame: Baseline to Week 52
Participants took part in the study from 23 September 2014 to 24 November 2022.
| Milestone | Stage 1 Arm 1: 2 g/kg Flebogamma® 5% DIF | Stage 1 Arm 2: 1 g/kg Flebogamma® 5% DIF | Stage 1 Arm 3: Placebo | Stage 2 Arm 1: 1 g/kg Flebogamma® 5% DIF | Stage 2 Arm 2: Placebo |
|---|---|---|---|---|---|
| Started | 42 | 42 | 42 | 33 | 32 |
| Completed | 25 | 34 | 33 | 26 | 26 |
| Not completed | 17 | 8 | 9 | 7 | 6 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 10 | 4 | 4 | 1 | 1 |
| Withdrew: Protocol violation | 2 | 0 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 4 | 2 | 2 | 3 | 4 |
| Withdrew: Reason not specified | 0 | 1 | 1 | 2 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 0 | 0 |
The 2MWD was used to assess physical performance by measuring the distance that a participant can quickly walk at a self-preferred speed on an indoor flat, hard surface 30 m (100-ft) hallway in a period of 2 minutes. A positive change from baseline indicates improvement (i.e. a patient can walk farther). Increase in distance walked (in meters) indicates improvement.
| meters (m) | Stage 1 Arm 1: 2 g/kg Flebogamma® 5% DIF | Stage 1 Arm 2: 1 g/kg Flebogamma® 5% DIF | Stage 1 Arm 3: Placebo | Stage 2 Arm 1: 1 g/kg Flebogamma® 5% DIF | Stage 2 Arm 2: Placebo |
|---|---|---|---|---|---|
| Baseline | 109.03 ± 30.564 | 112.55 ± 27.987 | 105.86 ± 31.942 | 101.18 ± 22.588 | 107.10 ± 30.167 |
| Change from Baseline at Week 52 | 7.50 ± 14.666 | 10.89 ± 19.067 | 3.17 ± 11.080 | 11.31 ± 12.108 | 5.65 ± 10.388 |
VAS is a participant self-reported pain scale used to evaluate the pain level in a 24 hours period. The scale consists of a 100 millimeters (mm) scale where 100 mm stands for the worst imaginable pain and zero stands for no pain. Higher scores indicate severe pain. A negative change from baseline indicates improvement. LS mean and 95% (CI) were based on MMRM method.
| millimeter (mm) | Flebogamma® 5% DIF 1 g/kg | Placebo |
|---|---|---|
| Change From Baseline in Pain Using Visual Analogue Scale (VAS) of Pain | -3.2 (-10.4 to 4.1) | -2.6 (-9.9 to 4.6) |
HRQoL SF-36 is participant self-reported survey.It yields 8-scale profile of functional health and well-being as well as physical and mental health summary measures. It consists of the subscales:physical functioning,limitations due to physical health,body pain,general health,vitality,social functioning,emotional problems, and mental health. Each domain score ranges from 0(worst) to 100(best),higher scores reflect better functional status.PCS is a subscale score \& give broader metric of physical HRQoL.PCS score ranges from 0 to 100 and is computed such that mean score of 50 corresponds to the general US population.Based on norm-based scoring,scores above 50 is better-than-average health \& below 50 is below-average health.Higher scores represents better physical health.Positive change from baseline indicates improvement.LS mean and 95% CI were based on MMRM.
| Score on a scale | Flebogamma® 5% DIF 1 g/kg | Placebo |
|---|---|---|
| Change From Baseline in Health-Related Quality of Life (HRQoL) Assessed by Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) Physical Component Summary (PCS) | 4.78 (1.9 to 7.6) | 2.79 (-0.1 to 5.7) |
The 6MWD was used to assess physical performance by measuring the distance that a patient can quickly walk at maximal speed on a flat, hard surface 30 m (100-ft) hallway in a period of 6 minutes. A positive change from baseline indicates improvement (i.e., a patient can walk farther). Increase from baseline in distance walked (in meters) indicated improvement. LS mean and 95% CI were based on MMRM method.
| meters (m) | Flebogamma® 5% DIF 1 g/kg | Placebo |
|---|---|---|
| Change From Baseline in Endurance Assessed by Six-Minute Walk Distance (6MWD) Test | 29.16 (7.54 to 50.78) | 13.36 (-8.22 to 34.95) |
Collected over From the start of study drug administration through 4 weeks after last study treatment (Up to Week 56). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Flebogamma® 5% DIF 2 g/kg | 0/42 (0%) | 3/42 (7.1%) | 36/42 (85.7%) |
| Flebogamma® 5% DIF 1 g/kg | 0/75 (0%) | 7/75 (9.3%) | 71/75 (94.7%) |
| Placebo | 0/74 (0%) | 9/74 (12.2%) | 60/74 (81.1%) |
| Event | Flebogamma® 5% DIF 2 g/kg | Flebogamma® 5% DIF 1 g/kg | Placebo |
|---|---|---|---|
| HypertensionVascular disorders | 0/42 | 0/75 | 2/74 |
| PneumoniaInfections and infestations | 0/42 | 0/75 | 2/74 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/42 | 0/75 | 0/74 |
| Myocardial infarctionCardiac disorders | 1/42 | 0/75 | 0/74 |
| PyelonephritisInfections and infestations | 1/42 | 0/75 | 0/74 |
| Miscarriage of partnerSocial circumstances | 0/42 | 0/75 | 1/74 |
| Ankle fractureInjury, poisoning and procedural complications | 0/42 | 0/75 | 1/74 |
| Bone fissureInjury, poisoning and procedural complications | 0/42 | 0/75 | 1/74 |
| SyncopeNervous system disorders | 0/42 | 0/75 | 1/74 |
| Food poisoningGastrointestinal disorders | 0/42 | 0/75 | 1/74 |
| Event | Flebogamma® 5% DIF 2 g/kg | Flebogamma® 5% DIF 1 g/kg | Placebo |
|---|---|---|---|
| HeadacheNervous system disorders | 27/42 | 39/75 | 23/74 |
| FatigueGeneral disorders | 14/42 | 22/75 | 20/74 |
| NauseaGastrointestinal disorders | 11/42 | 13/75 | 4/74 |
| ChillsGeneral disorders | 8/42 | 15/75 | 2/74 |
| PyrexiaGeneral disorders | 8/42 | 13/75 | 1/74 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 8/42 | 12/75 | 12/74 |
| DizzinessNervous system disorders | 3/42 | 4/75 | 13/74 |
| HypertensionVascular disorders | 7/42 | 12/75 | 8/74 |
| NasopharyngitisInfections and infestations | 4/42 | 8/75 | 11/74 |
| RashSkin and subcutaneous tissue disorders | 1/42 | 11/75 | 0/74 |
Intent-to-treat (ITT) population included all participants who were randomized.
| Age, Continuous(years) | Stage 1 Arm 1: 2 g/kg Flebogamma® 5% DIF | Stage 1 Arm 2: 1 g/kg Flebogamma® 5% DIF | Stage 1 Arm 3: Placebo | Stage 2 Arm 1: 1 g/kg Flebogamma® 5% DIF | Stage 2 Arm 2: Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 63.3 ± 6.24 | 62.3 ± 6.88 | 62.2 ± 7.22 | 65.1 ± 7.00 | 63.9 ± 6.26 | 63.2 ± 6.76 |
| Sex: Female, Male(Participants) | Stage 1 Arm 1: 2 g/kg Flebogamma® 5% DIF | Stage 1 Arm 2: 1 g/kg Flebogamma® 5% DIF | Stage 1 Arm 3: Placebo | Stage 2 Arm 1: 1 g/kg Flebogamma® 5% DIF | Stage 2 Arm 2: Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 23 | 21 | 27 | 22 | 22 | 115 |
| Male | 19 | 21 | 15 | 11 | 10 | 76 |
| Ethnicity (NIH/OMB)(Participants) | Stage 1 Arm 1: 2 g/kg Flebogamma® 5% DIF | Stage 1 Arm 2: 1 g/kg Flebogamma® 5% DIF | Stage 1 Arm 3: Placebo | Stage 2 Arm 1: 1 g/kg Flebogamma® 5% DIF | Stage 2 Arm 2: Placebo | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 6 | 6 | 4 | 1 | 20 |
| Not Hispanic or Latino | 39 | 36 | 36 | 29 | 31 | 171 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Stage 1 Arm 1: 2 g/kg Flebogamma® 5% DIF | Stage 1 Arm 2: 1 g/kg Flebogamma® 5% DIF | Stage 1 Arm 3: Placebo | Stage 2 Arm 1: 1 g/kg Flebogamma® 5% DIF | Stage 2 Arm 2: Placebo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 2 | 2 | 1 | 1 | 0 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 1 | 0 | 2 |
| White | 40 | 40 | 40 | 31 | 31 | 182 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2014 to primary completion in Nov 2022, 98 months.
Results were first posted in Dec 2025, 3 years after primary completion. A results delay was requested in Nov 2023.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immunoglobulins, Intravenous